ORIC Pharmaceuticals is a clinical-stage company developing rinzimetostat for metastatic prostate cancer and enozertinib for lung cancer with EGFR exon 20 or atypical mutations; neither is approved.
ORIC's case rests on rinzimetostat, an EED-binding allosteric PRC2 inhibitor, plus darolutamide in post-abiraterone mCRPC. Himalayas-1 compares the combination with an AR inhibitor or docetaxel, with rPFS primary and overall survival secondary. Enozertinib's first-line EGFR atypical lung cancer responses now support planned Redwood-1 registrational development, although durability remains immature. Management expects cash and investments to fund operations into 2H 2028, beyond the anticipated first rinzimetostat Phase 3 primary readout.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: Enozertinib supports a first-line registrational trial
Does enozertinib advance into Redwood-1 as planned, with further follow-up supporting the first-line atypical-mutation clinical profile?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Enozertinib responses support Redwood-1 plans alongside ongoing Himalayas-1
$125M private placement financing
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Blood cancers, Lung cancer, Other cancers
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
9 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.